Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 4, 2012, Pages 462-468

  Dogan, U ^a   Yavas, G ^b   Tekinalp, M ^c   Yavas, C ^d   Ata, O Y ^b   Ozdemir, K ^a  

^a NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

^b SELCUK UNIVERSITY   (Turkey)

^c Beyhekim State Hospital   (Turkey)

^d KONYA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

5 HT3 antagonists; Cardiac repolarization; Chemotherapy induced nausea and vomiting; Palonosetron; Tpeak to Tend interval; Transmural dispersion of repolarization

Indexed keywords

DEXAMETHASONE; PALONOSETRON; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HEART REPOLARIZATION; HUMAN; MALE; QT INTERVAL; REVIEW; SINGLE DRUG DOSE; T WAVE; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART ARRHYTHMIA; MIDDLE AGED; NAUSEA; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TURKEY (REPUBLIC); VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUINUCLIDINES; RISK ASSESSMENT; RISK FACTORS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TIME FACTORS; TURKEY; VOMITING;

EID: 84862681283     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. DE BOER-DENNERT M, DE WIT R, SCHMITZ PI, DJONTONO J, BEURDEN V, STOTER G, VERWEIJ J. Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists. Br J Cancer 1997; 76: 1055-1061.
2. SCHWARTZBERG L, MORROW G, BALU S, CRAVER C, GAYLE J, COX D. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States. Curr Med Res Opin; 27: 1613-1622.
3. PAVENTI S, SANTEVECCHI A, RANIERI R. Efficacy of a single-dose ondansetron for preventing post-operative nausea and vomiting after laparoscopic cholecystectomy with sevoflurane and remifentanil infusion anaesthesia. Eur Rev Med Pharmacol Sci 2001; 5: 59-63.
4. BENEDICT CR, ARBOGAST R, MARTIN L, PATTON L, MORRILL B, HAHNE W. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996; 28: 53-59.
5. BOIKE SC, ILSON B, ZARIFFA N, JORKASKY DK. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 1997; 54: 1172-1176.
6. BUYUKAVCI M, OLGUN H, CEVIZ N. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 2005; 28: 201-204.
7. PINARLI FG, ELLI M, DAGDEMIR A, BAYSAL K, ACAR S. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. Pediatr Blood Cancer 2006; 47: 567-571.
8. TURNER S, MATHEWS L, PANDHARIPANDE P, THOMPSON R. Dolasetron-induced torsades de pointes. J Clin Anesth 2007; 19: 622-625.
9. MCKECHNIE K, FROESE A. Ventricular tachycardia after ondansetron administration in a child with undiagnosed long QT syndrome. Can J Anaesth 2010; 57: 453-457.
10. CHANDRAKALA R, VIJAYASHANKARA CN, KUMAR KK, SARALA N. Ondansetron induced fatal ventricular tachycardia. Indian J Pharmacol 2008; 40: 186-187.
11. BAGULEY WA, HAY WT, MACKIE KP, CHENEY FW, CULLEN BF. Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide. Anesth Analg 1997; 84: 1380-1381.
12. LIKUN Z, XIANG J, YI B, XIN D, TAO ZL. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapyinduced nausea and vomiting in adults. Oncologist 2011; 16: 207-216.
13. BOTREL TE, CLARK OA, CLARK L, PALADINI L, FALEIROS E, PEGORETTI B. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: Systematic review and meta-analysis. Support Care Cancer 2011; 19: 823-832.
14. YAVAS C, DOGAN U, YAVAS G, ARAZ M, ATA OY. Acute effect of palonosetron on electrocardiographic parameters in cancer patients: A prospective study. Support Care Cancer 2011 Dec 15 [Epub ahead of print].
15. GONULLU G, DEMIRCAN S, DEMIRAG MK, ERDEM D, YUCEL I. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 2011 Jul 20 [Epub ahead of print].
16. COUDERC J, ZAREBA W. Assessment of ventricular repolarization from bodysurface ECGs in humans. In: Morganroth J, Gussak I. Cardiac safety of noncardiac drugs: Practical guidelines for clinical research and drug development. Totowa, N.J.: Humana Press; 2005.
17. XIA Y, LIANG Y, KONGSTAD O, LIAO Q, HOLM M, OLSSON B, YUAN S. In vivo validation of the coincidence of the peak and end of the T wave with full repolarization of the epicardium and endocardium in swine. Heart Rhythm 2005; 2: 162-169.
18. BLAND JM, ALTMAN DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
19. MORGANROTH J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 2007; 81: 108-113.
20. INTERNATIONAL CONFERENCE ON HARMONISATION; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist 2005; 70: 61134-61135.
21. ANTZELEVITCH C. Drug-induced spatial dispersion of repolarization. Cardiol J 2008; 15: 100-121.
22. GARSON A, JR., DICK M, 2ND, FOURNIER A, GILLETTE PC, HAMILTON R, KUGLER JD, VAN HARE GF, 3RD, VETTER V, VICK GW, 3RD. The long QT syndrome in children. An international study of 287 patients. Circulation 1993; 87: 1866-1872.
23. ANTZELEVITCH C. The M Cell. J Cardiovasc Pharmacol Ther 1997; 2: 73-76.
24. SHIMIZU M, INO H, OKEIE K, YAMAGUCHI M, NAGATA M, HAYASHI K, ITOH H, IWAKI T, OE K, KONNO T, MABUCHI H. T-peak to T-end interval may be a better predictor of high-risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin I mutation than QT dispersion. Clin Cardiol 2002; 25: 335-339.
25. WATANABE N, KOBAYASHI Y, TANNO K, MIYOSHI F, ASANO T, KAWAMURA M, MIKAMI Y, ADACHI T, RYU S, MIYATA A, KATAGIRI T. Transmural dispersion of repolarization and ventricular tachyarrhythmias. J Electrocardiol 2004; 37: 191-200.
26. TAKENAKA K, AI T, SHIMIZU W, KOBORI A, NINOMIYA T, OTANI H, KUBOTA T, TAKAKI H, KAMAKURA S, HORIE M. Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome. Circulation 2003; 107: 838-844.
27. PANIKKATH R, REINIER K, UY-EVANADO A, TEODORESCU C, HATTENHAUER J, MARIANI R, GUNSON K, JUI J, CHUGH SS. Prolonged Tpeak-to-tend interval on the resting ECG is associated with increased risk of sudden cardiac death. Circ Arrhythm Electrophysiol 2011; 4: 441-447.
28. GUPTA P, PATEL C, PATEL H, NARAYANASWAMY S, MALHOTRA B, GREEN JT, YAN GX. T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 2008; 41: 567-574.
29. CASTRO HEVIA J, ANTZELEVITCH C, TORNES BARZAGA F, DORANTES SANCHEZ M, DORTICOS BALEA F, ZAYAS MOLINA R, QUINONES PEREZ MA, FAYAD RODRIGUEZ Y. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006; 47: 1828-1834.
30. HAVRILLA PL, KANE-GILL SL, VERRICO MM, SEYBERT AL, REIS SE. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother 2009; 43: 532-536.
31. FAHY CJ, WARD I, HOPKINSON J. Broad complex tachycardia and tropisteron. Eur J Anaesthesiol 2008; 25: 864-865.
32. MITTERSCHIFFTHALER G, PUTZ G. Supraventricular tachycardia and ST segment depression after intravenous administration of tropisetron. Eur J Anaesthesiol 2006; 23: 86-87.
33. CHARBIT B, ALBALADEJO P, FUNCK-BRENTANO C, LEGRAND M, SAMAIN E, MARTY J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005; 102: 1094-1100.
34. CHAN MT, CHOI KC, GIN T, CHUI PT, SHORT TG, YUEN PM, POON AH, APFEL CC, GAN TJ. The additive interactions between ondansetron and droperidol for preventing postoperative nausea and vomiting. Anesth Analg 2006; 103: 1155-1162.
35. GRUNBERG SM, KOELLER JM. Palonosetron: A unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother 2003; 4: 2297-2303.
36. ROJAS C, STATHIS M, THOMAS AG, MASSUDA EB, ALT J, ZHANG J, RUBENSTEIN E, SEBASTIANI S, CANTOREGGI S, SNYDER SH, SLUSHER B. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008; 107: 469-478.
37. KURYSHEV YA, BROWN AM, WANG L, BENEDICT CR, RAMPE D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 2000; 295: 614-620.
38. SIDDIQUI MA, SCOTT LJ. Palonosetron. Drugs 2004; 64: 1125-1132; discussion 1133-1124.
39. BRUGNATELLI S, GATTONI E, GRASSO D, ROSSETTI F, PERRONE T, DANOVA M. Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients. Tumori 2011; 97: 362-366.
40. DI RENZO N, MONTANINI A, MANNINA D, DONDI A, MUCI S, MANCUSO S, DE PAOLIS MR, PLATI C, STELITANO C, PATTI C, OLIVIERI A, LIARDO E, BUDA G, CANTAFFA R, FEDERICO M. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: Results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Support Care Cancer 2011; 19: 1505-1510.
41. JACKSON MB, YAKEL JL. The 5-HT3 receptor channel. Annu Rev Physiol 1995; 57: 447-468.
42. NISHIO H, FUJII A, NAKATA Y. Re-examination for pharmacological properties of serotonin-induced tachycardia in isolated guinea-pig atrium. Behav Brain Res 1996; 73: 301-304.